Differentiation therapy of acute myeloid leukemia

E Gocek, E Marcinkowska - Cancers, 2011 - mdpi.com
Acute Myeloid Leukemia (AML) is a predominant acute leukemia among adults,
characterized by accumulation of malignantly transformed immature myeloid precursors. A …

The Use of 1α,25-Dihydroxyvitamin D3 as an Anticancer Agent

E Marcinkowska, GR Wallace, G Brown - International Journal of …, 2016 - mdpi.com
The notion that vitamin D can influence the incidence of cancer arose from epidemiological
studies. The major source of vitamin D in the organism is skin production upon exposure to …

MicroRNA-32 Upregulation by 1,25-Dihydroxyvitamin D3 in Human Myeloid Leukemia Cells Leads to Bim Targeting and Inhibition of AraC-Induced Apoptosis

E Gocek, X Wang, X Liu, CG Liu, GP Studzinski - Cancer research, 2011 - AACR
Dihydroxyvitamin D3 (1, 25D) used to treat human acute myeloid leukemia (AML) cells
induces features of normal monocytes, but the mechanisms underlying this response are not …

Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia

HJ Lee, JR Muindi, W Tan, Q Hu, D Wang, S Liu… - Cancer, 2014 - Wiley Online Library
BACKGROUND Several studies have suggested that low 25 (OH) vitamin D3 levels may be
prognostic in some malignancies, but no studies have evaluated their impact on treatment …

Regulation of Expression of CEBP Genes by Variably Expressed Vitamin D Receptor and Retinoic Acid Receptor α in Human Acute Myeloid Leukemia Cell Lines

A Marchwicka, E Marcinkowska - International journal of molecular …, 2018 - mdpi.com
All-trans-retinoic acid (ATRA) and 1α, 25-dihydroxyvitamin D (1, 25D) are potent inducers of
differentiation of myeloid leukemia cells. During myeloid differentiation specific transcription …

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

MA Spinner, A Aleshin, MT Santaguida… - Blood …, 2020 - ashpublications.org
Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are
appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute …

Vitamin D derivatives in acute myeloid leukemia: The matter of selecting the right targets

E Marcinkowska - Nutrients, 2022 - mdpi.com
Acute myeloid leukemia (AML) is an aggressive and often fatal hematopoietic malignancy. A
very attractive way to treat myeloid leukemia, called “differentiation therapy”, was proposed …

Perspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1, 25-dihydroxyvitamin D and …

A Marchwicka, M Cebrat, P Sampath… - Frontiers in …, 2014 - frontiersin.org
The concept of differentiation therapy of cancer is~ 40 years old. Despite many encouraging
results obtained in laboratories, both in vitro and in vivo studies, the only really successful …

Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation

E Gocek, A Marchwicka, H Baurska, A Chrobak… - The Journal of steroid …, 2012 - Elsevier
Some leukemic cell lines can be driven to differentiate to monocyte-like cells by 1, 25-
dihydroxyvitamin D3 (1, 25D) and to granulocyte-like cells by all-trans retinoic acid (ATRA) …

Diverse regulation of vitamin D receptor gene expression by 1, 25-dihydroxyvitamin D and ATRA in murine and human blood cells at early stages of their …

S Janik, U Nowak, A Łaszkiewicz, A Satyr… - International journal of …, 2017 - mdpi.com
Vitamin D receptor (VDR) is present in multiple blood cells, and the hormonal form of vitamin
D, 1, 25-dihydroxyvitamin D (1, 25D) is essential for the proper functioning of the immune …